Today, the definition of lung cancer is very different to what it was 20 years ago. It is no longer seen as a single disease. Each person with lung cancer has unique needs that should be addressed individually throughout their care journey. Yet lung cancer still has a significant impact on patients, their loved ones, healthcare systems and society. It remains the leading cause of cancer deaths and one of the most commonly diagnosed cancers in the world, with almost 2.5 million new cases diagnosed in 2022 alone.1 While research has transformed the lung cancer landscape over the past few decades, it is still one of the most difficult-to-treat cancers and patients face an ongoing need for improved outcomes.
At Roche, we are working closely with our partners – from patients and healthcare professionals to health systems and industry – to redefine the future of lung cancer care. Our approach goes beyond treatment. With our combined expertise in diagnostics, pharmaceuticals and digital health solutions, we are committed to reshaping the way we diagnose, treat and care for people with this disease - starting from early detection to personalised treatment and care.
As with all cancers, the early detection and treatment of lung cancer offers the best chance for more patients to come closer to cure. To address this, a critical component of our strategy is exploring new ways to test for lung cancer and detect more patients at earlier stages, to help find the right treatment for every person.
The key to combating cancer lies in knowing how it operates. Understanding different patients’ diseases, including the different genetic alterations or mechanisms that suppress the immune system, can help healthcare professionals deliver more personalised care for each individual patient. By applying our deep understanding of biology, data science and pioneering machine learning and computational technology, we are accelerating novel targeted therapies and immunotherapies that empower the body's immune system to fight cancer.
Our mission is to improve patient outcomes by translating cutting-edge scientific discoveries into tangible progress in care.
References:
1. World Health Organisation. World Globocan 2022. Available from:
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.